CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 145 filers reported holding CTI BIOPHARMA CORP in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $11,737,076 | -61.1% | 2,794,542 | -44.3% | 0.75% | -58.0% |
| Q4 2022 | $30,149,327 | +43.4% | 5,016,527 | +38.9% | 1.79% | +46.3% |
| Q3 2022 | $21,024,000 | +30.2% | 3,612,376 | +33.6% | 1.22% | -9.1% |
| Q2 2022 | $16,146,000 | +77.1% | 2,704,510 | +38.5% | 1.34% | +94.4% |
| Q1 2022 | $9,119,000 | +49.0% | 1,952,691 | -5.9% | 0.69% | +91.2% |
| Q3 2021 | $6,120,000 | +1326.6% | 2,074,714 | +1108.9% | 0.36% | +1348.0% |
| Q2 2021 | $429,000 | – | 171,619 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 3,904,400 | $3,355,000 | 2.31% |
| BVF INC/IL | 6,929,690 | $5,955,000 | 0.65% |
| CAXTON CORP | 324,452 | $279,000 | 0.32% |
| NEA Management Company, LLC | 3,750,000 | $3,222,000 | 0.23% |
| Orbimed Advisors | 5,000,000 | $4,297,000 | 0.07% |
| Fosun International Ltd | 459,274 | $390,000 | 0.03% |
| Paloma Partners Management Co | 229,800 | $197,000 | 0.00% |
| OXFORD ASSET MANAGEMENT LLP | 127,602 | $110,000 | 0.00% |
| LMR Partners LLP | 54,931 | $47,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 17,495 | $15,000 | 0.00% |